.png){kind=small}
.png){kind=small}
BackTable / Tumor Board / Contributor
Dr. Adam Burgoyne
Medical Oncologist
Dr. Adam Burgoyne is a gastrointestinal / hepatobiliary oncologist and associate clinical professor with Ochsner Health in New Orleans, Louisiana.
Listen to Dr. Adam Burgoyne on the BackTable Tumor Board Podcast
The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Adam Burgoyne and get practical advice on how to build your practice by listening to the BackTable Tumor Board Podcast.
Stay Up To Date
Follow:
Subscribe:
Sign Up:
About Dr. Adam Burgoyne
Adam Burgoyne, MD, PhD, is a board-certified medical oncologist who specializes in diagnosing and treating primary liver cancers such as hepatocellular carcinoma (HCC). He also treats cancers of the esophagus, gallbladder, pancreas, stomach, small intestine, colon and appendix, as well as gastrointestinal stromal tumors (GIST).
Dr. Burgoyne uses many forms of therapy, including traditional chemotherapy, immunotherapy and targeted therapy, with an emphasis on personalized medicine, to offer the best possible patient outcomes. Dr. Burgoyne is the medical oncologist for UC San Diego Health's multidisciplinary liver cancer clinic.
As a physician-scientist, Dr. Burgoyne also leads original research to improve survival rates among people with primary liver cancer and other cancers affecting the digestive system. In particular, he is working on developing novel drugs that inhibit multiple targets within the cancer cell with a single agent. He also studies tumor genetics and the biology of gastrointestinal stromal tumors (GIST) to facilitate personalized cancer care. His work has appeared in Journal of Translational Medicine, Molecular Cancer Therapeutics, and Cancer, among others.
Dr. Burgoyne completed a fellowship in hematology and oncology at UC San Diego School of Medicine, where he was chief fellow. He also completed a residency in internal medicine at UC San Diego School of Medicine. Dr. Burgoyne earned his medical degree and doctorate from Case Western Reserve University School of Medicine in Cleveland, Ohio. He is board-certified in internal medicine and medical oncology.
Dr. Burgoyne is a member of the American Association for Cancer Research, the American Association for the Study of Liver Diseases, the American Society of Hematology, and the American Society of Clinical Oncology. He is a member of the Alpha Omega Alpha Honor Medical Society.
Podcasts Featuring Dr. Adam Burgoyne
VI Episode #517
Treatment of hepatocellular carcinoma (HCC), like that of many other cancers, spans a spectrum from curative to palliative intent. To explore the "grey zone" of treatment goals for intermediate-stage HCC patients, Dr. Sabeen Dhand interviews a panel of experts in the field: medical oncologists Dr. Adam Burgoyne and Dr. Lingling Du, along with interventional radiologists Dr. Kirema Garcia-Reyes and Dr. Zachary Berman.
VI Episode #513
In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman.
Tumor Board Episode #9
Do you ever wish you could be a fly on the wall at a tumor board meeting? In this episode of BackTable, we’re excited to give you an insider’s view of the real case discussions that take place during hepatocellular carcinoma (HCC) tumor boards. Host Dr. Zach Berman sits down with a multidisciplinary team, including Drs. Adam Burgoyne (medical oncologist), Heather Patton (hepatologist), Siddharth Padia (interventional radiologist), and Gabriel Schnickel (transplant and hepatobiliary surgeon).
Tumor Board Episode #5
Treatment of hepatocellular carcinoma (HCC), like that of many other cancers, spans a spectrum from curative to palliative intent. To explore the "grey zone" of treatment goals for intermediate-stage HCC patients, Dr. Sabeen Dhand interviews a panel of experts in the field: medical oncologists Dr. Adam Burgoyne and Dr. Lingling Du, along with interventional radiologists Dr. Kirema Garcia-Reyes and Dr. Zachary Berman.
Tumor Board Episode #3
In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman.
Get Connected
Thank you for listening! If you have a question for Dr. Adam Burgoyne about a topic discussed on the BackTable Tumor Board Podcast, you can get in touch with this form. Please note that our contributors are not able to respond to every inquiry.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Podcasts
Topics
More Contributors
Dr. Aparna Baheti
Dr. Michael Barraza
Dr. Pilar Bayona
Dr. Christopher Beck
Dr. George Behrens
Dr. Zach Berman